Dorato Capital Management Buys Shares of 4,126 AbbVie Inc. $ABBV

Dorato Capital Management purchased a new position in AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 4,126 shares of the company’s stock, valued at approximately $916,000.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its position in AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after purchasing an additional 448,554 shares during the last quarter. Legal & General Group Plc raised its position in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after buying an additional 493,420 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the period. Amundi grew its position in AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in AbbVie by 4.4% during the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after buying an additional 408,426 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ABBV shares. Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $208.79 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The business has a fifty day moving average of $221.79 and a two-hundred day moving average of $224.48. The stock has a market cap of $369.17 billion, a PE ratio of 88.47, a PEG ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.